Brookstone Capital Management Has $534,000 Position in Exact Sciences Corporation $EXAS

Brookstone Capital Management lowered its holdings in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 5.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,054 shares of the medical research company’s stock after selling 535 shares during the quarter. Brookstone Capital Management’s holdings in Exact Sciences were worth $534,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Larson Financial Group LLC raised its position in Exact Sciences by 2,804.8% in the 1st quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock valued at $26,000 after buying an additional 589 shares during the last quarter. National Pension Service raised its position in Exact Sciences by 75.1% in the 1st quarter. National Pension Service now owns 681 shares of the medical research company’s stock valued at $29,000 after buying an additional 292 shares during the last quarter. SVB Wealth LLC acquired a new stake in Exact Sciences in the 1st quarter valued at approximately $30,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Exact Sciences in the 1st quarter valued at approximately $34,000. Finally, Banque Cantonale Vaudoise acquired a new stake in Exact Sciences in the 1st quarter valued at approximately $34,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Insider Activity at Exact Sciences

In other news, Director James Edward Doyle sold 2,000 shares of the business’s stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $60.00, for a total transaction of $120,000.00. Following the completion of the transaction, the director owned 57,962 shares of the company’s stock, valued at approximately $3,477,720. The trade was a 3.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.20% of the company’s stock.

Exact Sciences Price Performance

Exact Sciences stock opened at $64.64 on Monday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.56 and a current ratio of 2.89. Exact Sciences Corporation has a 52 week low of $38.81 and a 52 week high of $72.83. The stock has a market capitalization of $12.24 billion, a P/E ratio of -11.90, a price-to-earnings-growth ratio of 5.73 and a beta of 1.24. The stock has a fifty day moving average of $54.24 and a 200-day moving average of $51.91.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, August 6th. The medical research company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.24. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The company had revenue of $811.09 million during the quarter, compared to analysts’ expectations of $774.43 million. During the same quarter in the previous year, the firm earned ($0.09) EPS. Exact Sciences’s revenue was up 16.0% on a year-over-year basis. On average, sell-side analysts expect that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EXAS has been the topic of a number of recent research reports. Wall Street Zen raised Exact Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Wells Fargo & Company set a $68.00 price target on Exact Sciences in a research report on Wednesday, October 1st. UBS Group lowered their price target on Exact Sciences from $61.00 to $53.00 and set a “neutral” rating on the stock in a research report on Thursday, August 7th. Cowen reissued a “buy” rating on shares of Exact Sciences in a report on Thursday, August 7th. Finally, Barclays boosted their target price on Exact Sciences from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $69.90.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.